Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of a miRNA-based non-invasive predictive biomarker of response to target therapy in BRAF-mutant melanoma.
Ruggiero CF, Fattore L, Terrenato I, Sperati F, Salvati V, Madonna G, Capone M, Valenti F, Di Martino S, Mandoj C, Liguoro D, Castaldo V, Cafaro G, Simeone E, Vanella V, Russillo M, Conti L, Cuda G, Giannarelli D, Ascierto PA, Mancini R, Ciliberto G. Ruggiero CF, et al. Among authors: russillo m. Theranostics. 2022 Oct 24;12(17):7420-7430. doi: 10.7150/thno.77761. eCollection 2022. Theranostics. 2022. PMID: 36438490 Free PMC article.
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies.
Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F. Fabi A, et al. Among authors: russillo m. Breast. 2008 Oct;17(5):499-505. doi: 10.1016/j.breast.2008.03.006. Epub 2008 May 1. Breast. 2008. PMID: 18450443 Free article. Review.
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Metro G, Fabi A, Mirri MA, Vidiri A, Pace A, Carosi M, Russillo M, Maschio M, Giannarelli D, Pellegrini D, Pompili A, Cognetti F, Carapella CM. Metro G, et al. Among authors: russillo m. Cancer Chemother Pharmacol. 2010 Jan;65(2):391-7. doi: 10.1007/s00280-009-1155-x. Epub 2009 Oct 22. Cancer Chemother Pharmacol. 2010. PMID: 19847425 Clinical Trial.
Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.
Cuppone F, Bria E, Vaccaro V, Puglisi F, Fabi A, Sperduti I, Carlini P, Milella M, Nisticò C, Russillo M, Papaldo P, Ferretti G, Aapro M, Giannarelli D, Cognetti F. Cuppone F, et al. Among authors: russillo m. J Exp Clin Cancer Res. 2011 May 12;30(1):54. doi: 10.1186/1756-9966-30-54. J Exp Clin Cancer Res. 2011. PMID: 21569417 Free PMC article.
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F. Fabi A, et al. Among authors: russillo m. BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482. BMC Cancer. 2012. PMID: 23083011 Free PMC article.
Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials.
Rossi V, Berchialla P, Giannarelli D, Nisticò C, Ferretti G, Gasparro S, Russillo M, Catania G, Vigna L, Mancusi RL, Bria E, Montemurro F, Cognetti F, Fabi A. Rossi V, et al. Among authors: russillo m. Cancers (Basel). 2019 Oct 26;11(11):1661. doi: 10.3390/cancers11111661. Cancers (Basel). 2019. PMID: 31717791 Free PMC article.
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.
Fabi A, Mottolese M, Di Benedetto A, Sperati F, Ercolani C, Buglioni S, Nisticò C, Ferretti G, Vici P, Perracchio L, Malaguti P, Russillo M, Botti C, Pescarmona E, Cognetti F, Terrenato I. Fabi A, et al. Among authors: russillo m. Clin Breast Cancer. 2020 Dec;20(6):e761-e770. doi: 10.1016/j.clbc.2020.05.005. Epub 2020 May 13. Clin Breast Cancer. 2020. PMID: 32580907
63 results